Literature DB >> 25174649

Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats.

Jang-Won Lee1, Victor Tapias2, Roberto Di Maio3, J Timothy Greenamyre2, Jason R Cannon4.   

Abstract

Mutations in leucine-rich repeated kinase 2 (LRRK2) cause autosomal dominant late-onset Parkinson's disease (PD), and the G2019S mutation in the kinase domain of LRRK2 is the most common genetic cause of familial PD. Enhanced kinase activity of G2019S LRRK2 is a suspected mechanism for carriers to develop PD but pathophysiological function of G2019S LRRK2 is not clear. The objective of the present study was to characterize a bacterial artificial chromosome rat expressing human G2019S LRRK2. Immunoblotting analysis showed that G2019S LRRK2 expression was approximately 5-8 times higher than wild-type rat LRRK2. At ages of 4, 8, and 12 months, our characterization showed that expression of G2019S LRRK2 induced oxidative stress in striatum and substantia nigra, increased inducible nitric oxide synthase expression in nigral dopamine neurons, and abnormal morphology of nigral dopaminergic neurons in transgenic rats compared with wild-type, without inducing overt neurodegeneration in nigrostriatal dopaminergic neurons. Thus, we conclude that although this model does not reproduce the key features of end-stage PD, important preclinical features of the disease are evident, which may be useful in studying the earliest stages of PD and for gene-environment interaction studies.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Inflammation; Leucine-rich repeat kinase 2; Neurodegeneration; Oxidative stress; Parkinson's disease

Mesh:

Substances:

Year:  2014        PMID: 25174649      PMCID: PMC5289148          DOI: 10.1016/j.neurobiolaging.2014.07.011

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  49 in total

1.  Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone.

Authors:  Sheila M Fleming; Chunni Zhu; Pierre-Olivier Fernagut; Arpesh Mehta; Cheryl D DiCarlo; Ronald L Seaman; Marie-Françoise Chesselet
Journal:  Exp Neurol       Date:  2004-06       Impact factor: 5.330

2.  The role of LRRK2 in inflammatory bowel disease.

Authors:  Zhihua Liu; Michael J Lenardo
Journal:  Cell Res       Date:  2012-03-20       Impact factor: 25.617

3.  Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.

Authors:  Andrew B West; Rita M Cowell; João P L Daher; Mark S Moehle; Kelly M Hinkle; Heather L Melrose; David G Standaert; Laura A Volpicelli-Daley
Journal:  J Comp Neurol       Date:  2014-04-12       Impact factor: 3.215

4.  LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool.

Authors:  Giovanni Piccoli; Steven B Condliffe; Matthias Bauer; Florian Giesert; Karsten Boldt; Silvia De Astis; Andrea Meixner; Hakan Sarioglu; Daniela M Vogt-Weisenhorn; Wolfgang Wurst; Christian Johannes Gloeckner; Michela Matteoli; Carlo Sala; Marius Ueffing
Journal:  J Neurosci       Date:  2011-02-09       Impact factor: 6.167

5.  Bag1 is a regulator and marker of neuronal differentiation.

Authors:  P Kermer; M Krajewska; J M Zapata; S Takayama; J Mai; S Krajewski; J C Reed
Journal:  Cell Death Differ       Date:  2002-04       Impact factor: 15.828

6.  Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.

Authors:  Xianting Li; Jyoti C Patel; Jing Wang; Marat V Avshalumov; Charles Nicholson; Joseph D Buxbaum; Gregory A Elder; Margaret E Rice; Zhenyu Yue
Journal:  J Neurosci       Date:  2010-02-03       Impact factor: 6.167

Review 7.  The oxidant stress hypothesis in Parkinson's disease: evidence supporting it.

Authors:  S Fahn; G Cohen
Journal:  Ann Neurol       Date:  1992-12       Impact factor: 10.422

8.  Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease.

Authors:  Yanping Li; Wencheng Liu; Tinmarla F Oo; Lei Wang; Yi Tang; Vernice Jackson-Lewis; Chun Zhou; Kindiya Geghman; Mikhail Bogdanov; Serge Przedborski; M Flint Beal; Robert E Burke; Chenjian Li
Journal:  Nat Neurosci       Date:  2009-06-07       Impact factor: 24.884

Review 9.  Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.

Authors:  Payal N Gandhi; Shu G Chen; Amy L Wilson-Delfosse
Journal:  J Neurosci Res       Date:  2009-05-01       Impact factor: 4.164

10.  Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.

Authors:  Byoung Dae Lee; Joo-Ho Shin; Jackalina VanKampen; Leonard Petrucelli; Andrew B West; Han Seok Ko; Yun-Il Lee; Kathleen A Maguire-Zeiss; William J Bowers; Howard J Federoff; Valina L Dawson; Ted M Dawson
Journal:  Nat Med       Date:  2010-08-22       Impact factor: 53.440

View more
  24 in total

1.  Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.

Authors:  M Yue; K M Hinkle; P Davies; E Trushina; F C Fiesel; T A Christenson; A S Schroeder; L Zhang; E Bowles; B Behrouz; S J Lincoln; J E Beevers; A J Milnerwood; A Kurti; P J McLean; J D Fryer; W Springer; D W Dickson; M J Farrer; H L Melrose
Journal:  Neurobiol Dis       Date:  2015-03-31       Impact factor: 5.996

2.  Parkinson disease-associated LRRK2 G2019S transgene disrupts marrow myelopoiesis and peripheral Th17 response.

Authors:  Jeongho Park; Jang-Won Lee; Scott C Cooper; Hal E Broxmeyer; Jason R Cannon; Chang H Kim
Journal:  J Leukoc Biol       Date:  2017-07-27       Impact factor: 4.962

3.  PhIP exposure in rodents produces neuropathology potentially relevant to Alzheimer's disease.

Authors:  Tauqeerunnisa Syeda; Rachel M Foguth; Emily Llewellyn; Jason R Cannon
Journal:  Toxicology       Date:  2020-03-10       Impact factor: 4.221

4.  From the Cover: Alterations in Optineurin Expression and Localization in Pre-clinical Parkinson's Disease Models.

Authors:  John Pierce Wise; Jason Cannon
Journal:  Toxicol Sci       Date:  2016-07-29       Impact factor: 4.849

5.  Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production.

Authors:  Victor Tapias; Xiaoping Hu; Kelvin C Luk; Laurie H Sanders; Virginia M Lee; J Timothy Greenamyre
Journal:  Cell Mol Life Sci       Date:  2017-05-22       Impact factor: 9.261

6.  The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins.

Authors:  Mark S Moehle; João Paulo Lima Daher; Travis D Hull; Ravindra Boddu; Hisham A Abdelmotilib; James Mobley; George T Kannarkat; Malú G Tansey; Andrew B West
Journal:  Hum Mol Genet       Date:  2015-04-29       Impact factor: 6.150

7.  Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.

Authors:  João P L Daher; Hisham A Abdelmotilib; Xianzhen Hu; Laura A Volpicelli-Daley; Mark S Moehle; Kyle B Fraser; Elie Needle; Yi Chen; Stefanus J Steyn; Paul Galatsis; Warren D Hirst; Andrew B West
Journal:  J Biol Chem       Date:  2015-06-15       Impact factor: 5.157

8.  Neurodevelopmental Malformations of the Cerebellar Vermis in Genetically Engineered Rats.

Authors:  Raddy L Ramos; Sarah E Van Dine; Mary E Gilbert; Joerg R Leheste; German Torres
Journal:  Cerebellum       Date:  2015-12       Impact factor: 3.847

9.  Alterations in the nigrostriatal dopamine system after acute systemic PhIP exposure.

Authors:  Zeynep Sena Agim; Jason R Cannon
Journal:  Toxicol Lett       Date:  2018-01-31       Impact factor: 4.372

10.  Neuromelanin Modulates Heterocyclic Aromatic Amine-Induced Dopaminergic Neurotoxicity.

Authors:  Vivek Lawana; Se Young Um; Jean-Christophe Rochet; Robert J Turesky; Jonathan H Shannahan; Jason R Cannon
Journal:  Toxicol Sci       Date:  2020-01-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.